Figure 3 illustrates the potential synergistic benefits of second-generation incretin analogs (semaglutide and tirzepatide) and advanced technological devices used for diabetes management in patients with T1D, double diabetes and LADA. Here, GCG is linked to type 1 diabetes mellitus.